Nasdaq apls.

Apellis Pharmaceuticals (NASDAQ: APLS) shares plunged Monday on the back of a short report from Citron Research, which said the "happy days are over" for the company. The short-selling firm said ...9,367,396. 841,461. 11.1323. Back to APLS Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ...APLS Real-Time Quotes. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and ... Feb 22, 2023 · With the business potentially at an important milestone, we thought we'd take a closer look at Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) future prospects. Apellis Pharmaceuticals, Inc., a ... (NASDAQ: APLS) Apellis Pharmaceuticals currently has 118,499,945 outstanding shares. With Apellis Pharmaceuticals stock trading at $61.58 per share, the total ...

WALTHAM, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...Get 7 Days Free Sign In Sign In TopicsWALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company ...

Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.

Nasdaq provides an interactive stock information chart to view history. Downloadable stock history data table is also accessible by clicking on Data Table on the navigation tool bar. If you have ...WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the ...Apellis Pharmaceuticals (NASDAQ: APLS ) shares plunged Monday on the back of a short report from Citron Research, which said the "happy days are over" for the company. The short-selling firm said it has "reason to believe that CEO Cedric Francois is not being honest with Wall St. about the report cases of vasculitis" regarding the …08/15/2022. Option Execute. Direct. 12,500. $15.09. 55,407. Back to APLS Overview. Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and ... Under priority review status, the FDA has accepted Apellis Pharmaceuticals' (NASDAQ:APLS) marketing application seeking approval for pegcetacoplan for the treatment of paroxysmal nocturnal ...

28 de set. de 2022 ... (NASDAQ:APLS) for the first time. The company launched its flagship product Empaveli in 2021 and is currently pursuing other indications ...

Bill Oxford/iStock via Getty Images. Apellis Pharmaceuticals (NASDAQ:APLS) and Beam Therapeutics (NASDAQ:BEAM) will collaborate to develop therapies for complement-driven diseases.; The body's ...

Noteworthy Wednesday Option Activity: RUN, APLS, VRT. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sunrun Inc (Symbol: RUN), where a ...Apellis Pharmaceuticals (NASDAQ: APLS) 2% HIGHER; BofA Securities upgraded the stock from Neutral to Buy with a price target of $85.00 (from $52.00). After-hours movers: GitLab surges on earnings ...How much insider selling is happening at Apellis Pharmaceuticals? Insiders have sold a total of 851,250 Apellis Pharmaceuticals shares in the last 24 months for a total of $50,097,256.67 sold.WALTHAM, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its first ...Nov 2, 2023 · Reported EPS is $-1.17 EPS, expectations were $-0.86. Operator: Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Third Quarter 2023 Earnings ...

Number of Hedge Fund Shareholders: 36. The number of hedge funds long Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has ticked up steadily over each of the past four quarters, more than doubling ...value. Forecast 12 Month Forward PEG Ratio. -0.44. Investors are always looking for companies with good growth prospects selling at attractive prices. One popular statistic used to identify such ...WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (Nasdaq:APLS), a global biopharmaceutical company and leader in complement, today announced the closing of its ...Find the latest Earnings Report Date for Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com.WALTHAM, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced its second quarter 2020 financial results and business highlights.Analyst Price Forecast Suggests 156.95% Upside. As of July 6, 2023, the average one-year price target for Apellis Pharmaceuticals is 104.04. The forecasts range from a low of 76.76 to a high of ...

... Pharmaceuticals (NASDAQ: APLS). Wedbush Analyst forecast on APLS. Laura ChicoWedbush. 08/29/23. $29.00. Hold. -40.94%. Downside. Reiterated. Follow. 0. 0.

Apr 7, 2023 · The firm decreased its portfolio allocation in APLS by 48.09% over the last quarter. GSAOX - Goldman Sachs Small Cap Growth Insights Fund holds 13K shares representing 0.01% ownership of the company. The forecasts range from a low of 29.29 to a high of $99.75. The average price target represents an increase of 53.76% from its latest reported closing price of 43.31. See our leaderboard of ...Funds + ETFs. After-Hours Quotes. See All Market Activity->. News + Insights.21 февр. 2023 г. ... On today's stock market, APLS stock surged 5.4% to close at 58.50. ... *Real-time prices by Nasdaq Last Sale. Realtime quote and/or trade prices ...WALTHAM, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET. The conference will be …USA. Published on June 4, 2021. venBio, a Palo Alto, CA and San Francisco, CA-based closed its fourth life sciences venture capital fund, venBio Global Strategic Fund IV, LP, at approximately ...

WALTHAM Mass., May 06, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved ...

Apellis Pharmaceuticals, Inc. Common Stock (APLS) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.

Feb 17, 2023 · WALTHAM, Mass., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the U.S. Food and ... Apellis Pharmaceuticals ( NASDAQ:APLS – Get Free Report) last issued its quarterly earnings results on Wednesday, November 1st. The company reported ($1.17) EPS for the quarter, missing analysts ...Advertisement. Apellis Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View APLS financial statements in full.Nov 29, 2023 · The public float for APLS is 96.80M and currently, short sellers hold a 16.67% of that float. On November 29, 2023, APLS’s average trading volume was 2.29M shares. APLS) stock’s latest price update. Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 5.56relation to previous closing price of 47.16. Our analysis of options history for Apellis Pharmaceuticals APLS revealed 35 unusual trades. Delving into the details, we found 62% of traders were bullish, while 37% showed bearish tendencies ...On October 12, 2023, Brian Cheng, an analyst at BofA Securities, expressed his viewpoint on Apellis Pharmaceuticals (NASDAQ:APLS). Despite maintaining a Neutral rating, Cheng increased the price target for the company from $44 to $46. It is worth noting that Apellis Pharmaceuticals has garnered a Strong Buy consensus among analysts, who have set a …Dec 1, 2023 · 14 analysts have issued twelve-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $29.00 to $93.00. On average, they anticipate the company's share price to reach $66.50 in the next twelve months. This suggests a possible upside of 8.0% from the stock's current price. Apellis Pharmaceuticals Inc (NASDAQ: APLS) revealed a comprehensive corporate restructuring plan aimed at catalyzing the growth of its flagship products, Syfovre (pegcetacoplan injection) and

Advertisement. Apellis Pharmaceuticals Inc. balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View APLS financial statements in full.WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its ...Apellis Pharmaceuticals ( NASDAQ: APLS) can't seem to shake off safety concerns with its vision loss drug Syfovre (pegcetacoplan) and is down another ~6% on Tuesday. Adding to the company's woes ...Apellis Pharmaceuticals (NASDAQ:APLS) and Intra-Cellular Therapies (NASDAQ:ITCI) are both mid-cap medical companies, but which is the better stock?We will compare the two companies based on the strength of their risk, analyst recommendations, community ranking, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.Instagram:https://instagram. ginnie mae bonds rates todaycareington dental reviewscaptrust raleightiktok.challenges Headline. APLS Jan 2025 120.000 put. finance.yahoo.com - November 23 at 9:19 AM. Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 3.7% After Insider Selling. americanbankingnews.com - November 23 at 1:49 AM. Alec Machiels Sells 1,250 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock. americanbankingnews.com - November 22 at 4:44 AM. franklin rising dividends fundliberty media john malone Noteworthy Wednesday Option Activity: RUN, APLS, VRT. Among the underlying components of the Russell 3000 index, we saw noteworthy options trading …Find the latest press releases from Apellis Pharmaceuticals, Inc. Common Stock (APLS) at Nasdaq.com. pimco mint Jul 28, 2023 · As of Q1 2023, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) was the most commonly held stock out of the 12 stocks with biggest upside potential according to analysts. Its shares were held by 42 of ... 1832 Asset Management L.P. lifted its position in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 405.5% in the 2nd quarter, according to its most …